<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02507050</url>
  </required_header>
  <id_info>
    <org_study_id>1060</org_study_id>
    <nct_id>NCT02507050</nct_id>
  </id_info>
  <brief_title>Ivabradine and Post-revascularisation Microcirculatory Dysfunction</brief_title>
  <acronym>MICRO-PCI</acronym>
  <official_title>Can Ivabradine Attenuate Post-revascularisation Microcirculatory Dysfunction in Flow Limiting Coronary Artery Disease?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liverpool Heart and Chest Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liverpool Heart and Chest Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to test whether, in patients with angina and flow limiting epicardial&#xD;
      coronary artery disease, pre-treatment with Ivabradine, as opposed to beta blockers, will&#xD;
      reduce post percutaneous coronary intervention induced microvascular dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will be recruiting patients with stable angina referred for percutaneous intervention&#xD;
      (PCI) due to flow limiting coronary artery disease. All patients will be on an existing beta&#xD;
      blocker prescription (standard first line angina therapy). Our hypothesis is that Ivabradine&#xD;
      will attenuate microvascular dysfunction post PCI when compared to standard beta-blocker&#xD;
      pre-treatment. We intend to test this in a randomised, open-label parallel arm study with a&#xD;
      direct comparison between Ivabradine and beta-blockers (standard therapy). Patients will be&#xD;
      randomised to receive either Ivabradine (and stop beta blockers) or continue beta blockers&#xD;
      for 6 weeks prior to the PCI procedure. The primary endpoint will be IMR (index of&#xD;
      microvascular resistance) post PCI, as a marker of microvascular dysfunction and procedural&#xD;
      related myocardial injury. IMR is a potent marker of adverse outcome in STEMI patients and in&#xD;
      ACS after PCI. Although this has yet to be assessed in the elective setting, a reduction in&#xD;
      IMR with Ivabradine may indicate a potential to improve outcomes and lessen iatrogenic&#xD;
      microvascular dysfunction post PCI. IMR is assessed using thermodilution catheters placed&#xD;
      distal to the coronary stenosis and by producing hyperaemia. To assess the medium term&#xD;
      effects on the microcirculation post PCI all patients will have a stress perfusion cardiac&#xD;
      MRI 12 weeks post procedure. The secondary endpoint will be proportion of patients with&#xD;
      coronary flow reserve (CFR) &lt;2.0 in PCI territory (regional myocardial blood flow at&#xD;
      hyperaemia by intravenous adenosine infusion compared to rest). We will also be assessing CFI&#xD;
      (collateral flow index), as promotion of the collateral system is one method by which&#xD;
      Ivabradine may lessen procedural related myocardial injury, and ΔIMR as the difference&#xD;
      between IMR pre and post-PCI.&#xD;
&#xD;
      The measurement of cardiac troponins and use of cardiac MRI will facilitate the&#xD;
      identification of peri-procedural myocardial injury and procedural related myocardial&#xD;
      infarction as further secondary end points. The Seattle Angina Questionnaire will be used at&#xD;
      3 intervals to assess symptoms throughout the study. The total study length for each patient&#xD;
      will be 18 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding not yet achieved&#xD;
  </why_stopped>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IMR (Index of Microvascular Resistance)</measure>
    <time_frame>Immediately after PCI</time_frame>
    <description>Invasive marker of microvascular dysfunction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peri-procedural Troponin Release</measure>
    <time_frame>3 hours after PCI</time_frame>
    <description>Rise in high sensitivity troponin 3 hours after PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CFI pre-revascularisation</measure>
    <time_frame>Immediately prior to PCI</time_frame>
    <description>Collateral flow index is an invasively measured marker of collateral blood flow- to be measured prior to PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Improvement (Seattle Angina Questionnaire)</measure>
    <time_frame>18 weeks</time_frame>
    <description>Seattle Angina Questionnaire assessed at 18 weeks after starting treatment (12 weeks after PCI) and compared to baseline scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary Flow Reserve</measure>
    <time_frame>12 weeks</time_frame>
    <description>Coronary Flow Reserve measured in target vessel on MRI at 12 weeks after PCI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Angina</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomised to stop beta blockers and start Ivabradine. Initial dose of 5mg BD, titrated to 7.5mg BD if possible.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Bisoprolol given as standard beta blocker treatment i.e. Bisoprolol (maximum dose 10mg OD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>To start Ivabradine 6 weeks prior to PCI.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Procoralan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptoms of Angina Pectoris&#xD;
&#xD;
          2. Angiographic evidence of epicardial coronary artery stenosis referred for PCI&#xD;
&#xD;
          3. Flow limiting lesion (Fractional Flow Reserve ≤0.80) in one of following locations (as&#xD;
             defined in SYNTAX trial89):&#xD;
&#xD;
               1. Proximal or mid left anterior descending artery (LAD)&#xD;
&#xD;
               2. Proximal or mid dominant right coronary artery (RCA)&#xD;
&#xD;
               3. Proximal left circumflex artery (LCx) or 1ST Obtuse marginal Vessel&#xD;
&#xD;
          4. Existing beta blocker prescription&#xD;
&#xD;
          5. Echocardiogram performed within preceding 12 months&#xD;
&#xD;
          6. Patient consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous myocardial infarction (MI) in target vessel myocardial territory or any MI in&#xD;
             preceding 12 months (defined by patient history, ECG changes and evidence of regional&#xD;
             wall motion abnormalities on echocardiography)&#xD;
&#xD;
          2. FFR&gt;0.80 in target vessel at time of procedure&#xD;
&#xD;
          3. Requirement for Multi-vessel intervention in a single procedure&#xD;
&#xD;
          4. Any chronic total occlusion (100% epicardial occlusion) on angiography&#xD;
&#xD;
          5. Distal coronary artery stenosis or that affecting non-dominant RCA&#xD;
&#xD;
          6. Heart Rate &lt;60 bpm at inclusion (assessed by 12 lead ECG after minimum 10 minutes rest&#xD;
             period)&#xD;
&#xD;
          7. Any rhythm other than sinus rhythm&#xD;
&#xD;
          8. Sick sinus syndrome or high grade atrio-ventricular block&#xD;
&#xD;
          9. Permanent Pacemaker in situ&#xD;
&#xD;
         10. Congenital QT Syndrome&#xD;
&#xD;
         11. Intolerance or allergy to beta-blockers&#xD;
&#xD;
         12. Intolerance to Ivabradine&#xD;
&#xD;
         13. Additional (other than angina pectoris) indication for beta-blocker treatment e.g.&#xD;
             ventricular tachycardia&#xD;
&#xD;
         14. Concurrent required use of rate-limiting drugs other than beta-blockers&#xD;
&#xD;
         15. The necessity of combination therapy with Ivabradine and bisoprolol to achieve heart&#xD;
             rate control&#xD;
&#xD;
         16. Contraindication to Magnetic Resonance Imaging or IV adenosine&#xD;
&#xD;
         17. Severe impairment of renal function (eGFR&lt;30ml/min)&#xD;
&#xD;
         18. Severe Liver Disease (Any worse than Grade A by Child-Pugh Classification)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleem Khand, MBChB MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool Heart and Chest Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <last_update_submitted>August 16, 2018</last_update_submitted>
  <last_update_submitted_qc>August 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ivabradine</keyword>
  <keyword>Microvascular dysfunction</keyword>
  <keyword>PCI</keyword>
  <keyword>Procedural related myocardial injury</keyword>
  <keyword>IMR</keyword>
  <keyword>Index of Microvascular Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

